RÉSUMÉ
INTRODUCTION: In recent years, industrial production of Cannabis sativa has increased due to increased demand of medicinal products based on the plant. In these medicinal products, it is mainly the contents of cannabinoids like THCA and CBDA which are of interest, but also the flavonoids of C. sativa have pharmaceutical interest. OBJECTIVES: The primary aim is to study the distribution of the different cannabinoids in leaves of C. sativa and specifically to which extent they are located on the trichomes found on the surface of C. sativa leaves. Desorption electrospray ionization (DESI) and matrix assisted laser desorption ionization (MALDI) mass spectrometry imaging (MSI) provide non-targeted imaging of numerous compounds in the same experiment. Therefore, the distribution of flavonoids is also mapped in the same experiments. MATERIAL AND METHODS: Fan leaves from C. sativa were imaged in the lateral dimension using direct DESI-MSI as well as indirect DESI-MSI via a porous PTFE surface using pixel sizes of 150-200 µm. For cross sections of sugar leaves, MALDI-MSI was performed at 20 µm pixel size. RESULTS: From indirect DESI-MSI experiments, a connection was made between the cannabinoid CBGA and capitate-stalked trichomes. Other cannabinoids like THCA/CBDA (isomers, which are not resolved in an MSI experiment) were also detected in the capitate-stalked trichomes, but in addition to this also in the small glandular trichomes. MALDI-MSI experiments on cross sections of sugar leaves confirmed that the cannabinoids were not an integral part of the leaf tissue itself, but originated from the trichomes on the surface of the leaf. CONCLUSION: The study provides visual evidence that the cannabinoids are produced and accumulated in the trichomes of C. sativa leaves.
Sujet(s)
Cannabinoïdes , Cannabis , Cannabinoïdes/analyse , Cannabis/composition chimique , Spectrométrie de masse MALDI , Trichomes/composition chimique , Flavonoïdes/analyse , Feuilles de plante/composition chimique , Sucres/analyseRÉSUMÉ
SORL1 is strongly associated with both sporadic and familial forms of Alzheimer's disease (AD), but a lack of information about alternatively spliced transcripts currently limits our understanding of the role of SORL1 in AD. Here, we describe a SORL1 transcript (SORL1-38b) characterized by inclusion of a novel exon (E38b) that encodes a truncated protein. We identified E38b-containing transcripts in several brain regions, with the highest expression in the cerebellum and showed that SORL1-38b is largely located in neuronal dendrites, which is in contrast to the somatic distribution of transcripts encoding the full-length SORLA protein (SORL1-fl). SORL1-38b transcript levels were significantly reduced in AD cerebellum in three independent cohorts of postmortem brains, whereas no changes were observed for SORL1-fl. A trend of lower 38b transcript level in cerebellum was found for individuals carrying the risk variant at rs2282649 (known as SNP24), although not reaching statistical significance. These findings suggest synaptic functions for SORL1-38b in the brain, uncovering novel aspects of SORL1 that can be further explored in AD research.
Sujet(s)
Épissage alternatif , Maladie d'Alzheimer/génétique , Maladie d'Alzheimer/métabolisme , Dendrites/métabolisme , Protéines apparentées au récepteur LDL/génétique , Protéines apparentées au récepteur LDL/métabolisme , Protéines de transport membranaire/génétique , Protéines de transport membranaire/métabolisme , Épissage alternatif/génétique , Autopsie , Encéphale/métabolisme , Cervelet/anatomopathologie , Études de cohortes , Dendrites/génétique , Femelle , Prédisposition génétique à une maladie , Cellules HEK293 , Humains , Protéines apparentées au récepteur LDL/analyse , Mâle , Protéines de transport membranaire/analyse , Neurones/métabolisme , Banques de tissusRÉSUMÉ
Attention deficit hyperactivity disorder (ADHD) is the most frequently diagnosed neurodevelopmental disorder worldwide. Affected individuals present with hyperactivity, inattention, and cognitive deficits and display a characteristic paradoxical response to drugs affecting the dopaminergic system. However, the underlying pathophysiology of ADHD and how this relates to dopaminergic transmission remains to be fully understood. Sorcs2-/- mice uniquely recapitulate symptoms reminiscent of ADHD in humans. Here, we show that lack of SorCS2 in mice results in lower sucrose intake, indicating general reward deficits. Using in-vivo recordings, we further find that dopaminergic transmission in the ventral tegmental area (VTA) is shifted towards a more regular firing pattern with marked reductions in the relative occurrence of irregular firing in Sorcs2-/- mice. This was paralleled by abnormal acute behavioral responses to dopamine receptor agonists, suggesting fundamental differences in dopaminergic circuits and indicating a perturbation in the balance between the activities of the postsynaptic dopamine receptor DRD1 and the presynaptic inhibitory autoreceptor DRD2. Interestingly, the hyperactivity and drug response of Sorcs2-/- mice were markedly affected by novelty. Taken together, our findings show how loss of a candidate ADHD-risk gene has marked effects on dopaminergic circuit function and the behavioral response to the environment.
Sujet(s)
Trouble déficitaire de l'attention avec hyperactivité , Animaux , Trouble déficitaire de l'attention avec hyperactivité/génétique , Dopamine , Souris , Protéines de tissu nerveux , Récepteurs de surface cellulaire , Récepteurs dopaminergiques , Récompense , Aire tegmentale ventraleRÉSUMÉ
The ADAMTS9 rs4607103 C allele is one of the few gene variants proposed to increase the risk of type 2 diabetes through an impairment of insulin sensitivity. We show that the variant is associated with increased expression of the secreted ADAMTS9 and decreased insulin sensitivity and signaling in human skeletal muscle. In line with this, mice lacking Adamts9 selectively in skeletal muscle have improved insulin sensitivity. The molecular link between ADAMTS9 and insulin signaling was characterized further in a model where ADAMTS9 was overexpressed in skeletal muscle. This selective overexpression resulted in decreased insulin signaling presumably mediated through alterations of the integrin ß1 signaling pathway and disruption of the intracellular cytoskeletal organization. Furthermore, this led to impaired mitochondrial function in mouse muscle-an observation found to be of translational character because humans carrying the ADAMTS9 risk allele have decreased expression of mitochondrial markers. Finally, we found that the link between ADAMTS9 overexpression and impaired insulin signaling could be due to accumulation of harmful lipid intermediates. Our findings contribute to the understanding of the molecular mechanisms underlying insulin resistance and type 2 diabetes and point to inhibition of ADAMTS9 as a potential novel mode of treating insulin resistance.
Sujet(s)
Protéine ADAMTS9/métabolisme , Matrice extracellulaire/métabolisme , Insuline/métabolisme , Muscles squelettiques/métabolisme , Protéine ADAMTS9/génétique , Allèles , Animaux , Humains , Immunohistochimie , Insulinorésistance/génétique , Insulinorésistance/physiologie , Antigènes CD29/métabolisme , Mâle , Souris , Souris de lignée C57BL , Souris knockoutRÉSUMÉ
Coronary artery disease is the main cause of death worldwide and accelerated by increased plasma levels of cholesterol-rich low-density lipoprotein particles (LDL). Circulating PCSK9 contributes to coronary artery disease by inducing lysosomal degradation of the LDL receptor (LDLR) in the liver and thereby reducing LDL clearance. Here, we show that liver heparan sulfate proteoglycans are PCSK9 receptors and essential for PCSK9-induced LDLR degradation. The heparan sulfate-binding site is located in the PCSK9 prodomain and formed by surface-exposed basic residues interacting with trisulfated heparan sulfate disaccharide repeats. Accordingly, heparan sulfate mimetics and monoclonal antibodies directed against the heparan sulfate-binding site are potent PCSK9 inhibitors. We propose that heparan sulfate proteoglycans lining the hepatocyte surface capture PCSK9 and facilitates subsequent PCSK9:LDLR complex formation. Our findings provide new insights into LDL biology and show that targeting PCSK9 using heparan sulfate mimetics is a potential therapeutic strategy in coronary artery disease.PCSK9 interacts with LDL receptor, causing its degradation, and consequently reduces the clearance of LDL. Here, Gustafsen et al. show that PCSK9 interacts with heparan sulfate proteoglycans and this binding favors LDLR degradation. Pharmacological inhibition of this binding can be exploited as therapeutic intervention to lower LDL levels.
Sujet(s)
Protéoglycanes à sulfate d'héparane/métabolisme , Proprotéine convertase 9/métabolisme , Récepteurs aux lipoprotéines LDL/métabolisme , Anticorps/pharmacologie , Sites de fixation , Antienzymes/pharmacologie , Cellules HepG2 , Héparine/composition chimique , Héparine/pharmacologie , Hépatocytes/métabolisme , Humains , Inhibiteurs de PCSK9 , Proprotéine convertase 9/composition chimique , Proprotéine convertase 9/génétique , ProtéolyseRÉSUMÉ
Displaced dual-mode imaging (DDI) is introduced as a method for simultaneous imaging in positive and negative-ion mode on the same sample with desorption electrospray ionization imaging, as well as a method for simultaneous imaging in full-scan and tandem mass spectrometry (MS/MS) mode. DDI is performed by using a smaller row distance in the y-direction than the desired image resolution and recording for example every second row in positive-ion mode and the other half of the rows in negative-ion mode, thus resulting in two separate images. This causes some degree of oversampling, which is thus utilized to obtain complementary mass spectrometric of the sample. Imaging with both polarities is exemplified on an imprint of a Hypericum perforatum leaf containing secondary metabolites which ionize in both polarites and a mouse kidney containing phospholipids which ionize in positive or negative mode only. Simultaneous full-scan and MS/MS imaging was demonstrated on the same mouse kidney, as the mouse had been given a relatively low dose of the antidepressive drug amitriptyline. While the full-scan data allowed imaging of the endogenous phospholipids, the drug and its metabolites were only visible in the MS/MS images. The latter approach is useful, for example in whole-body imaging experiments where the full-scan data gives an overview of the tissue, and the MS/MS mode provides the sensitivity to image trace amounts of drugs and metabolites.
Sujet(s)
Amitriptyline/analyse , Antidépresseurs/analyse , Hypericum/composition chimique , Rein/composition chimique , Feuilles de plante/composition chimique , Spectrométrie de masse ESI/méthodes , Amitriptyline/administration et posologie , Amitriptyline/métabolisme , Animaux , Antidépresseurs/administration et posologie , Antidépresseurs/métabolisme , Rein/métabolisme , Mâle , Souris , Souris de lignée BALB CRÉSUMÉ
N-acylphosphatidylethanolamine (NAPE) and N-acylplasmenylethanolamine (pNAPE) are widely found phospholipids, and they are precursors for N-acylethanolamines, a group of compounds that has a variety of biological effects and encompasses the endocannabinoid anandamide. NAPE and pNAPE are synthesized by the transfer of an acyl chain from a donor phospholipid, to the amine in phosphatidylethanolamine or plasmenylethanolamine. NAPE has been reported to stabilize model membranes during brain ischemia, and to modulate food intake in rodents, thus having bioactive effects besides its precursor role. This paper reviews the metabolism, occurrence and assay of NAPE and pNAPE, and discusses the putative biological functions in mammals of these phospholipids. This article is part of a Special Issue entitled Phospholipids and Phospholipid Metabolism.
Sujet(s)
Acides arachidoniques/métabolisme , Endocannabinoïdes/métabolisme , Éthanolamines/métabolisme , Phosphatidyléthanolamine/métabolisme , Amides gras polyinsaturés N-alkylés/métabolisme , Rodentia/métabolisme , Transduction du signal/physiologie , Acylation , Animaux , Régulation de l'appétit/physiologie , Acides arachidoniques/composition chimique , Encéphale/métabolisme , Endocannabinoïdes/composition chimique , Éthanolamines/composition chimique , Humains , Lysosomes/métabolisme , Phosphatidyléthanolamine/composition chimique , Phospholipase D/métabolisme , Amides gras polyinsaturés N-alkylés/composition chimique , Type C Phospholipases/métabolismeRÉSUMÉ
Spatial synthesis of N-acyl-phosphatidylethanolamines (NAPEs) and N-acylethanolamines (NAEs) during ischemia-reperfusion in neonatal rats has been investigated and compared to the spatial degradation of other phospholipids. Ischemia was induced in anesthetized Wistar P7 rat pups by left middle cerebral artery electrocoagulation combined with a transient and concomitant occlusion of both common carotid arteries. Pups were sacrificed after 24 and 48 h. Sham-treated animals were sacrificed after 48 h. The frozen brains were sliced and subjected to desorption electrospray ionization imaging mass spectrometry. There was a remarkable increase in the levels of many species of NAPEs in the whole injured area at both time points, and a clear but minor increase in selected NAEs. In the ischemic area, the sodium adducts of phosphatidylcholine and of lyso-phosphatidylcholine accumulated and the potassium adduct of phosphatidylcholine disappeared, indicating breakdown of the Na(+)/K(+) pump. Free fatty acids, e.g., arachidonic and docosahexaenoic acids, tended to be more abundant in the periphery than in the center of the ischemic area and showed different spatial distribution. NAPEs are synthesized in the whole ischemic area where the cells seem to be dead and other phospholipids are degraded. Free fatty acids can be found in the periphery of the ischemic area.
Sujet(s)
Chimie du cerveau , Encéphalopathie ischémique/métabolisme , Lipides/analyse , Phosphatidyléthanolamine/analyse , Lésion d'ischémie-reperfusion/métabolisme , Animaux , Animaux nouveau-nés , Éthanolamines/analyse , Acide gras libre/métabolisme , Femelle , Infarctus du territoire de l'artère cérébrale moyenne/métabolisme , Mâle , Phosphatidyléthanolamine/métabolisme , Acétalphosphatides/métabolisme , Rats , Rat Wistar , Spectrométrie de masse ESIRÉSUMÉ
OBJECTIVE: Dietary fat is thought to stimulate release of incretin hormones via activation of fatty acid receptors in the intestine. However, dietary fat (triacylglycerol) is digested to 2-monoacylglycerol and fatty acids. Activation of G protein-coupled receptor 119 (GPR119) stimulates glucagon-like peptide-1 (GLP-1) release from the intestinal L-cells. We aimed to investigate if 2-oleoyl glycerol (2OG) can activate GPR119 in vitro and stimulate GLP-1 secretion in vivo. RESEARCH DESIGN AND METHODS: Agonist activity for various lipids was tested on transiently expressed human GPR119 in COS-7 cells. The effect of a jejunal bolus of 2 g 2OG on plasma levels of GLP-1 was evaluated in eight healthy human volunteers. The effect of 2OG was compared to an equimolar amount of oleic acid, a degradation product from 2OG, and the vehicle, glycerol. Digestion of 5 ml olive oil with pancreatic lipase will result in formation of approximately 2 g 2OG and 3.2 g oleic acid. RESULTS: 2OG and other 2-monoacylglycerols increased intracellular concentrations of cAMP in GPR119-expressing COS-7 cells (2OG EC(50) = 2.5 µm). Administration of 2OG to humans significantly increased plasma GLP-1 (0-25 min) when compared to the two controls, oleic acid and vehicle. Plasma levels of glucose-dependent insulinotropic polypeptide also increased. CONCLUSION: 2OG and other 2-monoacylglycerols formed during fat digestion can activate GPR119 and cause incretin release from the human intestine. This mechanism is likely to contribute to the known stimulatory effect of dietary fat on incretin secretion, and it indicates that GPR119 is a fat sensor.
Sujet(s)
Cellules entéroendocrines/métabolisme , Glucagon-like peptide 1/métabolisme , Glycérides/métabolisme , Récepteurs couplés aux protéines G/agonistes , Adulte , Glycémie/métabolisme , AMP cyclique/métabolisme , Cellules entéroendocrines/effets des médicaments et des substances chimiques , Glycérides/pharmacologie , Humains , Mâle , Acides oléiques/métabolisme , Acides oléiques/pharmacologieRÉSUMÉ
N-acyl-phosphatidylethanolamine is a precursor phospholipid for anandamide, oleoylethanolamide, and other N-acylethanolamines, and it may in itself have biological functions in cell membranes. Recently, N-palmitoyl-phosphatidylethanolamine (NAPE) has been reported to function as an anorectic hormone secreted from the gut and acting on the brain (Gillum et al., [5]). In the current study, two of our laboratories independently investigated whether NAPE metabolites may be involved in mediating the anorectic action of NAPE i.p. injected in mice. Thus, the anorectic activity of a non-hydrolysable NAPE analogue, having ether bonds instead of ester bonds at sn1 and sn2 was compared with that of NAPE in molar equivalent doses. Furthermore, the anorectic effect of NAPE in NAPE-hydrolysing phospholipase D knockout animals was investigated. As negative controls, the NAPE precursor phosphatidylethanolamine and the related phospholipids phosphatidylcholine and phosphatidic acid were also tested. All compounds except one were found to inhibit food intake, raising the possibility that the effect of NAPE is non-specific.
Sujet(s)
Anorexigènes/pharmacologie , Consommation alimentaire/effets des médicaments et des substances chimiques , Phosphatidyléthanolamine/pharmacologie , Animaux , Anorexigènes/composition chimique , Anorexigènes/métabolisme , Comportement animal/effets des médicaments et des substances chimiques , Mâle , Souris , Souris de lignée C57BL , Souris knockout , Structure moléculaire , Activité motrice/effets des médicaments et des substances chimiques , Phosphatidyléthanolamine/composition chimique , Phosphatidyléthanolamine/métabolisme , Phospholipase D/génétique , Phospholipase D/métabolismeRÉSUMÉ
This study was undertaken to investigate the link between dietary fat content and intestinal levels of anorectic N-acylethanolamines (NAEs), including oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and linoleoylethanolamide (LEA). Male rats were fed high-fat diets (HFDs) with variable percentages of fat [20-45% of total energy (E%)] for 1-7 d; afterward, the jejunums were isolated, and jejunal NAE levels were measured by liquid-chromatography mass spectrometry. Enzyme activities and mRNA expression levels were measured for two synthesizing enzymes, N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD) and glycerophosphodiesterase (GDE1), and one degrading enzyme, fatty acid amide hydrolase (FAAH). We found a dose-response relation between the quantity/percentage of dietary fat, irrespective of the energy density, and the reduction of intestinal levels of OEA, PEA, and LEA. The reductions were present after 1 d of 45E% HFD. LEA, the major NAE species, was shown to have an anorectic potency slightly less than that of OEA but higher than PEA. Regulation at the enzyme level seems not to explain the changes in NAE levels. The results suggest the presence of a fat sensor, mediating the reduced intestinal NAE levels. The intestinal NAE levels are reduced in a dose- and time-dependent manner in response to dietary fat intake, and this may contribute to the well-known hyperphagic effect of HFDs.